These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 9544741)

  • 1. Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice.
    Leppänen P; Luoma JS; Hofker MH; Havekes LM; Ylä-Herttuala S
    Atherosclerosis; 1998 Jan; 136(1):147-52. PubMed ID: 9544741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study.
    Gijbels MJ; van der Cammen M; van der Laan LJ; Emeis JJ; Havekes LM; Hofker MH; Kraal G
    Atherosclerosis; 1999 Mar; 143(1):15-25. PubMed ID: 10208477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van den Maagdenberg AM; Gijbels MJ; van der Boom H; HogenEsch H; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1994 Apr; 93(4):1403-10. PubMed ID: 8163645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice.
    de Winther MP; Gijbels MJ; van Dijk KW; van Gorp PJ; suzuki H; Kodama T; Frants RR; Havekes LM; Hofker MH
    Atherosclerosis; 1999 Jun; 144(2):315-21. PubMed ID: 10407492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development.
    Hiltunen TP; Luoma JS; Nikkari T; Ylä-Herttuala S
    Circulation; 1998 Mar; 97(11):1079-86. PubMed ID: 9531255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development.
    Georgiadi A; Wang Y; Stienstra R; Tjeerdema N; Janssen A; Stalenhoef A; van der Vliet JA; de Roos A; Tamsma JT; Smit JW; Tan NS; Müller M; Rensen PC; Kersten S
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1529-37. PubMed ID: 23640487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.
    Moore KJ; Kunjathoor VV; Koehn SL; Manning JJ; Tseng AA; Silver JM; McKee M; Freeman MW
    J Clin Invest; 2005 Aug; 115(8):2192-201. PubMed ID: 16075060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.
    Purcell-Huynh DA; Farese RV; Johnson DF; Flynn LM; Pierotti V; Newland DL; Linton MF; Sanan DA; Young SG
    J Clin Invest; 1995 May; 95(5):2246-57. PubMed ID: 7738190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII).
    Häkkinen T; Karkola K; Ylä-Herttuala S
    Virchows Arch; 2000 Oct; 437(4):396-405. PubMed ID: 11097365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.
    Podrez EA; Poliakov E; Shen Z; Zhang R; Deng Y; Sun M; Finton PJ; Shan L; Febbraio M; Hajjar DP; Silverstein RL; Hoff HF; Salomon RG; Hazen SL
    J Biol Chem; 2002 Oct; 277(41):38517-23. PubMed ID: 12145296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized cholesterol in the diet accelerates the development of atherosclerosis in LDL receptor- and apolipoprotein E-deficient mice.
    Staprans I; Pan XM; Rapp JH; Grunfeld C; Feingold KR
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):708-14. PubMed ID: 10712395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
    J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage.
    Lutgens E; Daemen M; Kockx M; Doevendans P; Hofker M; Havekes L; Wellens H; de Muinck ED
    Circulation; 1999 Jan; 99(2):276-83. PubMed ID: 9892595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific interaction of oxidized low-density lipoprotein with macrophage-derived foam cells isolated from rabbit atherosclerotic lesions.
    de Vries HE; Buchner B; van Berkel TJ; Kuiper J
    Arterioscler Thromb Vasc Biol; 1999 Mar; 19(3):638-45. PubMed ID: 10073968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).
    Callow MJ; Verstuyft J; Tangirala R; Palinski W; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1639-46. PubMed ID: 7657833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.
    Bellosta S; Mahley RW; Sanan DA; Murata J; Newland DL; Taylor JM; Pitas RE
    J Clin Invest; 1995 Nov; 96(5):2170-9. PubMed ID: 7593602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
    Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG
    J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum.
    Palinski W; Ord VA; Plump AS; Breslow JL; Steinberg D; Witztum JL
    Arterioscler Thromb; 1994 Apr; 14(4):605-16. PubMed ID: 7511933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.